

InnoCan Pharma

I ? . Ž ((f \$ L & \$ + ' - , - \$, %
 B 5 . Ž % * (* , - * ' \$ *)
 5 I Ž * % & ' - & , \$ \$ + \$ \$
 UWjcb4 dfcUWfj Y]bj Ygřcfq"Věa

21:55 19 Oct 2020

Innocan Pharma says Relief & Go CBD spray delivered pain relief to 90% of participants in clinical study

Innocan Pharma Corporation (CSE:INNO) announced Monday that 90% of participants in a clinical study of the company's Relief & Go over-the-counter (OTC) spray experienced a reduction in pain 24 hours after use.

The study, conducted by the Center for Podiatric Care & Sports Medicine in New York, included 18 people with pain ranging in area from the upper back to the feet.

After 20 minutes, 83% of participants noticed improvement, the company said, which jumped to 95% after an hour. After a full 24 hours, 90% described relief from pain.

READ: Innocan Pharma's cosmetic clinical study indicates 90% wrinkle reduction in volunteers using SHIR Premium CBD Facial Serum

Fifteen of the 18 participants would recommend the spray, the company said.

"We are thrilled that our clinical test yielded such promising results," CEO Iris Bincovich said in a statement. "Our unique approach and deep experience is exemplified in these impressive results that I'm certain are only the beginning."

The test was run by Joself Geldwert, who has more than 40 years of experience in foot surgery, biomechanics and sports injuries. He also serves on Innocan's scientific advisory committee.

"I have been following up with patients who I have been seeing for foot and ankle related problems that have been using Relief & Go pain relief spray, and their responses have been positive," Geldwert said. "I am impressed by how well patients have been doing with a non-prescriptive OTC pain relief spray."

Innocan's pain relief formulation contains a combination of magnesium oil, methyl salicylate, menthol and CBD, administered with a simple dose of spray, roll-on or lotion. Relief & Go spray is designed to target pain-related muscle and provide relief for joint pain.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Price: 0.41

Market Cap: \$72.04 m

1 Year Share Price Graph



January 2020 July 2020 January 2021

Share Information

Code: INNO

Listing: CSE

52 week	High	Low
	0.42	0.05

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).